---
figid: PMC8723792__nihms-1753820-f0003
figtitle: Translational science of cancers with SWI/SNF complex aberrations
organisms:
- Homo sapiens
- Mus musculus
- Saccharomyces cerevisiae
- Drosophila melanogaster
organisms_ner:
- Homo sapiens
- Mus musculus
- Drosophila melanogaster
- Danio rerio
pmcid: PMC8723792
filename: nihms-1753820-f0003.jpg
figlink: /pmc/articles/PMC8723792/figure/F3/
number: F3
caption: 'Illustration of reported vulnerabilities of cancers with loss-of-function
  mutations in SWI/SNF-complex genes, depicting both therapeutic opportunities supported
  only by preclinical evidence and treatments currently being evaluated in ongoing
  clinical trials (). The therapeutic targets include: residual SWI/SNF complexes,,,;
  Polycomb repressive complex 2 (PRC2), mainly its enzymatic subunit, enhancer of
  Zeste homologue 2 (EZH2), and predominantly in SMARCB1-mutant or SMARCA4-mutant,;
  components of the DNA damage repair pathway, in particular, poly(ADP-ribose) polymerase
  (PARP) and ATR in ARID1A-mutant cancers,; and receptor tyrosine kinases (RTKs) in
  several cancers enriched for mutations in SWI/SNF-complex genes, in a context-specific
  manner,,,. Targeting of Aurora A or CDK4/6 (cell-cyle kinases), MDM2 (a negative
  regulator of the tumour suppressor p53), autophagy or the proteasome could also
  be of potential therapeutic benefit in patients with cancers harbouring particular
  SWI/SNF-complex abberations,,,. Additionally, mutations in several genes encoding
  SWI/SNF-complex subunits have been associated with sensitivity to immune-checkpoint
  inhibitors targeting programmed cell death 1 (PD-1) or programmed cell death 1 ligand
  1 (PD-L1),–,,. ARID1A, AT-rich interactive domain-containing protein 1A; bromodomain-containing
  protein 9, BRD9; FGFR1, fibroblast growth factor receptor 1; HDACs, histone deacetylases;
  PDGFR, platelet-derived growth factor receptor; SMARCA2/4, SWI/SNF-related matrix-associated
  actin-dependent regulator of chromatin subfamily A member 2 or 4.'
papertitle: The SWI/SNF complex in cancer — biology, biomarkers and therapy.
reftext: Priya Mittal, et al. Nat Rev Clin Oncol. ;17(7):435-448.
year: '2020'
doi: 10.1038/s41571-020-0357-3
journal_title: Nature reviews. Clinical oncology
journal_nlm_ta: Nat Rev Clin Oncol
publisher_name: ''
keywords: ''
automl_pathway: 0.9567283
figid_alias: PMC8723792__F3
figtype: Figure
redirect_from: /figures/PMC8723792__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8723792__nihms-1753820-f0003.html
  '@type': Dataset
  description: 'Illustration of reported vulnerabilities of cancers with loss-of-function
    mutations in SWI/SNF-complex genes, depicting both therapeutic opportunities supported
    only by preclinical evidence and treatments currently being evaluated in ongoing
    clinical trials (). The therapeutic targets include: residual SWI/SNF complexes,,,;
    Polycomb repressive complex 2 (PRC2), mainly its enzymatic subunit, enhancer of
    Zeste homologue 2 (EZH2), and predominantly in SMARCB1-mutant or SMARCA4-mutant,;
    components of the DNA damage repair pathway, in particular, poly(ADP-ribose) polymerase
    (PARP) and ATR in ARID1A-mutant cancers,; and receptor tyrosine kinases (RTKs)
    in several cancers enriched for mutations in SWI/SNF-complex genes, in a context-specific
    manner,,,. Targeting of Aurora A or CDK4/6 (cell-cyle kinases), MDM2 (a negative
    regulator of the tumour suppressor p53), autophagy or the proteasome could also
    be of potential therapeutic benefit in patients with cancers harbouring particular
    SWI/SNF-complex abberations,,,. Additionally, mutations in several genes encoding
    SWI/SNF-complex subunits have been associated with sensitivity to immune-checkpoint
    inhibitors targeting programmed cell death 1 (PD-1) or programmed cell death 1
    ligand 1 (PD-L1),–,,. ARID1A, AT-rich interactive domain-containing protein 1A;
    bromodomain-containing protein 9, BRD9; FGFR1, fibroblast growth factor receptor
    1; HDACs, histone deacetylases; PDGFR, platelet-derived growth factor receptor;
    SMARCA2/4, SWI/SNF-related matrix-associated actin-dependent regulator of chromatin
    subfamily A member 2 or 4.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CD274
  - ATR
  - ANTXR1
  - MMAB
  - SERPINA2
  - MDM2
  - TP53
  - TP63
  - TP73
  - CDK6
  - CDK4
  - PARP1
  - COL11A2
  - PARP2
  - PARP3
  - PARP4
  - PARP6
  - PARP8
  - PARP9
  - PARP10
  - PARP11
  - PARP12
  - PARP14
  - PARP15
  - PARP16
  - TNKS
  - TNKS2
  - TIPARP
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - FGFR1
  - PDGFRB
  - PDGFRA
  - EZH2
  - EED
  - EZH1
  - SUZ12
  - SMARCA1
  - SMARCA2
  - SMARCA4
  - ARID1B
  - BRD9
  - PSMA1
  - PSMA2
  - PSMA3
  - PSMA4
  - PSMA5
  - PSMA6
  - PSMA7
  - PSMA8
  - PSMB1
  - PSMB10
  - PSMB2
  - PSMB3
  - PSMB4
  - PSMB5
  - PSMB6
  - PSMB7
  - PSMB8
  - PSMB9
  - PSMC1
  - PSMC2
  - PSMC3
  - PSMC4
  - PSMC5
  - PSMC6
  - PSMD1
  - PSMD10
  - PSMD11
  - PSMD12
  - PSMD13
  - PSMD14
  - PSMD2
  - PSMD3
  - PSMD4
  - PSMD5
  - PSMD6
  - PSMD7
  - PSMD8
  - PSMD9
  - PSME1
  - PSME2
  - PSME3
  - PSMF1
  - SEM1
  - USP5
  - HDAC9
  - HDAC1
  - HDAC2
  - HDAC3
  - HDAC8
  - HDAC4
  - HDAC5
  - HDAC7
  - HDAC6
  - HDAC10
  - SIRT1
  - SIRT2
  - SIRT3
  - SIRT4
  - SIRT5
  - SIRT6
  - SIRT7
  - HDAC11
  - Cd274
  - Atr
  - Mmab
  - Mdm2
  - Trp53
  - Cdk6
  - Cdk4
  - Parp1
  - Aurka
  - Pik3r1
  - Fgfr1
  - Pdgfrb
  - Ezh2
  - Smarca2
  - Smarca4
  - Arid1b
  - Brd9
  - CycE
  - cyc
  - mei-41
  - put
  - RYa-R
  - p53
  - betaTub60D
  - hth
  - Parp
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Tie
  - Ras85D
  - InR
  - btl
  - E(z)
  - Me
  - snf
  - hfw
  - Iswi
  - Brd7-9
  - si:ch211-241b2.5
  - atr
  - mdm2
  - tp53
  - cdk6
  - cdk4
  - parp14rs2.1
  - fgfr1a
  - ezh2
  - smarca2
  - smarca4a
  - hpxb
  - arid1b
  - brd9
---
